Last 12 months
Inside the activity.
0 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2017 Filed Dec 15, 2017 22:13 UTC |
Schumacher Laura JExecutive Vice President
|
SaleCommon stock, $0.01 par value | 144,367 | $96.71 | $13,961,270.60 |
DisclosureSEC source: 0001179110-17-015438 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,732 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.50 to $97.44, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 22:13 UTC |
Schumacher Laura JExecutive Vice President
|
Exercise / conversionCommon stock, $0.01 par value | 144,367 | $35.88 | $5,179,887.96 |
DisclosureSEC source: 0001179110-17-015438 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2017 Filed Dec 11, 2017 22:23 UTC |
Gosebruch Henry OChief Strategy Officer
|
Tax withholdingCommon stock, $0.01 par value | 14,235 | $95.95 | $1,365,848.25 |
DisclosureSEC source: 0001179110-17-015227 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,902 Read SEC document |
| November 21, 2017 Filed Nov 24, 2017 16:55 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 218,193 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-17-014593 · edgar.xml · derivative · entry 6 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,097 Underlying: Common stock, $0.01 par value · 218,193 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 21, 2017 Filed Nov 24, 2017 16:55 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 218,193 | $94.01 | $20,511,800.27 |
DisclosureSEC source: 0001179110-17-014593 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,837 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.75 to $94.34, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 21, 2017 Filed Nov 24, 2017 16:55 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Exercise / conversionCommon stock, $0.01 par value | 218,193 | $58.88 | $12,847,203.84 |
DisclosureSEC source: 0001179110-17-014593 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 22:26 UTC |
SEVERINO MICHAELEVP, R&D and CSO
|
SaleCommon stock, $0.01 par value | 25,633 | $94.69 | $2,427,211.84 |
DisclosureSEC source: 0001179110-17-014053 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,922 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.50 to $94.89, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2017 Filed Nov 13, 2017 17:25 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GiftCommon stock, $0.01 par value | 2,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-014052 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,837 Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 21:04 UTC |
Gosebruch Henry OChief Strategy Officer
|
SaleCommon stock, $0.01 par value | 100 | $92.02 | $9,202.00 |
DisclosureSEC source: 0001179110-17-013599 · edgar.xml · nonDerivative · entry 4 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,137 Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 21:04 UTC |
Gosebruch Henry OChief Strategy Officer
|
SaleCommon stock, $0.01 par value | 4,482 | $91.22 | $408,849.38 |
DisclosureSEC source: 0001179110-17-013599 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,237 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.95 to $91.84, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 21:04 UTC |
Gosebruch Henry OChief Strategy Officer
|
SaleCommon stock, $0.01 par value | 11,568 | $90.49 | $1,046,813.77 |
DisclosureSEC source: 0001179110-17-013599 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,719 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.94 to $90.94, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 21:04 UTC |
Gosebruch Henry OChief Strategy Officer
|
SaleCommon stock, $0.01 par value | 2,150 | $89.38 | $192,171.95 |
DisclosureSEC source: 0001179110-17-013599 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,287 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.93 to $89.86, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 20:32 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 73 | $88.86 Strike: $0.00 | $6,486.78 |
DisclosureSEC source: 0001179110-17-012953 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,589 Underlying: Common Stock · 73 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 16:32 UTC |
TILTON GLENN FDirector
|
GrantStock Equivalent Units · Derivative | 422 | $88.86 Strike: $0.00 | $37,498.92 |
DisclosureSEC source: 0001179110-17-012954 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,503 Underlying: Common Stock · 422 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 16:32 UTC |
LIDDY EDWARD MDirector
|
GrantStock Equivalent Units · Derivative | 351 | $88.86 Strike: $0.00 | $31,189.86 |
DisclosureSEC source: 0001179110-17-012955 · edgar.xml · derivative · entry 1 LIDDY EDWARD M · CIK 0001188983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,147 Underlying: Common stock · 351 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend equivalent reinvestment feature. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 20:32 UTC |
RAPP EDWARD JDirector
|
GrantStock Equivalent Units · Derivative | 368 | $88.86 Strike: $0.00 | $32,700.48 |
DisclosureSEC source: 0001179110-17-012956 · edgar.xml · derivative · entry 1 RAPP EDWARD J · CIK 0001171780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,971 Underlying: Common Stock · 368 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 17:02 UTC |
Michael Robert A.VP, Controller
|
SaleCommon stock, $0.01 par value | 6,699 | $88.00 | $589,512.00 |
DisclosureSEC source: 0001179110-17-012766 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,007 Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:19 UTC |
Schumacher Laura JExecutive Vice President
|
GiftCommon stock, $0.01 par value | 2,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-012200 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,732 Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
Exercise / conversionOption (right to buy) · Derivative | 4,800 | $0.00 Strike: $24.21 | $0.00 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · derivative · entry 9 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 4,800 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
SaleCommon stock, $0.01 par value | 2,338 | $85.06 | $198,870.28 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · nonDerivative · entry 6 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,799 Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
SaleCommon stock, $0.01 par value | 1,030 | $85.04 | $87,591.20 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · nonDerivative · entry 5 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,137 Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
SaleCommon stock, $0.01 par value | 132 | $85.03 | $11,223.96 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · nonDerivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,167 Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
SaleCommon stock, $0.01 par value | 3,600 | $85.00 | $305,982.00 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,299 Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
SaleCommon stock, $0.01 par value | 1,200 | $84.99 | $101,988.00 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,899 Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 21:40 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
Exercise / conversionCommon stock, $0.01 par value | 4,800 | $24.21 | $116,199.36 |
DisclosureSEC source: 0001179110-17-012208 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 193,131 | $0.00 Strike: $51.42 | $0.00 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · derivative · entry 19 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 193,131 shares Expires 2024-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 1,200 | $71.03 | $85,236.00 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 15 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,492 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 9,618 | $71.01 | $682,974.18 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 14 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,692 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 446 | $71.04 | $31,681.61 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 13 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,310 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 3,158 | $71.02 | $224,281.16 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 12 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,756 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 2,602 | $71.04 | $184,846.08 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 11 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,914 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 1,100 | $71.05 | $78,149.50 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 10 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,516 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 157,163 | $71.00 | $11,158,573.00 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 9 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,616 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 1,800 | $71.06 | $127,908.00 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 8 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,779 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 1,153 | $71.02 | $81,880.30 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 7 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,579 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 6,200 | $71.05 | $440,510.00 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 6 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,732 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 3 | $71.07 | $213.20 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 5 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,932 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 100 | $71.06 | $7,105.50 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 4 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,935 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 1,809 | $71.03 | $128,484.23 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,035 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 6,779 | $71.01 | $481,342.90 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,844 Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 19:26 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Exercise / conversionCommon stock, $0.01 par value | 193,131 | $51.42 | $9,930,796.02 |
DisclosureSEC source: 0001179110-17-011244 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 22,038 | $0.00 Strike: $51.42 | $0.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · derivative · entry 16 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,131 Underlying: Common stock · 22,038 shares Expires 2024-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 737 | $71.13 | $52,422.81 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 11 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,492 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 200 | $71.11 | $14,222.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 10 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,229 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 500 | $71.11 | $35,552.50 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 9 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,429 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 1,900 | $71.08 | $135,052.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 8 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,929 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 3,000 | $71.07 | $213,210.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 7 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,829 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 15,600 | $71.06 | $1,108,536.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 6 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,829 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
SaleCommon stock, $0.01 par value | 101 | $71.00 | $7,171.00 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 5 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,429 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 17:01 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Exercise / conversionCommon stock, $0.01 par value | 22,038 | $51.42 | $1,133,193.96 |
DisclosureSEC source: 0001179110-17-011152 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.